Actively Recruiting
Evaluating a 4-Month Short Treatment for Low Risk Active Pulmonary Tuberculosis Compared to the Standard 6-Month Regimen
Led by Kaohsiung Veterans General Hospital. · Updated on 2026-08-03
270
Participants Needed
8
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Tuberculosis remains a major global health issue, and efforts to end the epidemic by 2030 are ongoing. Taiwan, while seeing a decline in TB cases, remains an endemic area. This trial studies adults with newly diagnosed pulmonary tuberculosis at low risk of recurrence, aiming to evaluate a shorter, 4-month treatment regimen compared to the standard 6-month course. The goal is to improve treatment completion rates and reduce TB transmission while lessening the burden on public health systems. Participants will be randomly assigned to receive either a 4-month regimen consisting of two months of isoniazid, rifampin, pyrazinamide, and ethambutol followed by two months of isoniazid, rifampin, and ethambutol, or the standard 6-month regimen with two months of the same four drugs followed by four months of three drugs. The study spans three years with planned enrollment of 270 patients divided evenly between the two groups. Throughout the study, participants will undergo various assessments including sputum culture tests, blood tests measuring immune markers, and monitoring for adverse events. Outcomes such as TB disease-free survival at 12 and 24 months after treatment, sputum culture conversion, mortality rates, and changes in inflammatory markers will be evaluated. Safety and treatment adherence will be closely followed during the treatment and post-treatment periods, with the total study duration lasting up to 24 months post-randomization for outcomes.
CONDITIONS
Brief Title
Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial
Research Team
S
Susan Shin-Jung Lee, M.D., Ph.D.
M
Mei-Ling Lin, University
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here